Actively Recruiting
Feasibility Study of Daratumumab Combined with Dose-Adjusted EPOCH Chemotherapy in Patients with Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
Led by AIDS Malignancy Consortium · Updated on 2026-10-28
15
Participants Needed
9
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of daratumumab with dose-adjusted EPOCH chemotherapy in treating patients newly diagnosed with stage I-IV plasmablastic lymphoma. Plasmablastic lymphoma cells produce high levels of CD38, a protein targeted by daratumumab, a monoclonal antibody. This combination may help the immune system attack cancer cells and limit their growth and spread. The study aims to assess feasibility, response rates, safety, and survival outcomes in both HIV-positive and HIV-negative patients. Participants receive daratumumab intravenously on specific days during each 21-day cycle, along with continuous intravenous chemotherapy drugs etoposide, doxorubicin hydrochloride, vincristine sulfate, oral prednisone, and intravenous cyclophosphamide. Treatment can continue for up to 6 cycles unless the disease progresses or unacceptable side effects occur. After completing treatment, patients are followed for up to 2 years to monitor outcomes. During the study, patients undergo evaluations including tumor measurements and safety assessments. Researchers measure how many patients complete at least 3 cycles of treatment, response rates according to established criteria, adverse events, and survival outcomes over 1 year. Additional exploratory tests include tumor biology analyses and viral DNA monitoring. Follow-up visits occur every 3 months for up to 2 years after treatment ends to track health and disease status.
CONDITIONS
Brief Title
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here